Prelude Therapeutics (PRLD) Reiterated at Market Outperform by Citizens: 'Well-Capitalized'
Tweet Send to a Friend
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $3.00 price target on Prelude Therapeutics (NASDAQ: PRLD).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
